Stock 3341 NIHON CHOUZAI CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings NIHON CHOUZAI Co.,Ltd.

Equities

3341

JP3729200000

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-07-12 am EDT 		5-day change 1st Jan Change
1,504 JPY +0.47% Intraday chart for NIHON CHOUZAI Co.,Ltd. -0.20% +7.51%
Jul. 09 Nihon Chouzai Included Again in FTSE Blossom Japan Index, Blossom Japan Sector Relative Index MT
Jun. 04 Infosys Develops Medication Guidance Mobile App for Japan's Nihon Chouzai MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • With a P/E ratio at 10.21 for the current year and 8.47 for next year, earnings multiples are highly attractive compared with competitors.
  • The company shows low valuation levels, with an enterprise value at 0.19 times its sales.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company has a low valuation given the cash flows generated by its activity.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Sector: Drug Retailers

1st Jan change Capi. Investor Rating ESG Refinitiv
NIHON CHOUZAI CO.,LTD. Stock NIHON CHOUZAI Co.,Ltd.
+7.51% 282M -
RAIA DROGASIL S.A. Stock Raia Drogasil S.A.
-12.38% 8.02B
B
AIN HOLDINGS INC. Stock Ain Holdings Inc.
+25.86% 1.2B -
QOL HOLDINGS CO., LTD. Stock Qol Holdings Co., Ltd.
-8.03% 356M -
SALUS, LJUBLJANA, D. D. Stock SALUS, Ljubljana, d. d.
+8.89% 225M - -
PETMED EXPRESS, INC. Stock PetMed Express, Inc.
-48.15% 77.42M
C
GREEN CROSS HEALTH LIMITED Stock Green Cross Health Limited
-21.10% 72.82M - -
MEDICAL IKKOU GROUP CO.,LTD. Stock Medical Ikkou Group Co.,Ltd.
+28.21% 62.34M - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 3341 Stock
  4. Ratings NIHON CHOUZAI Co.,Ltd.